Breaking Down Sun Pharmaceutical Industries Limited Financial Health: Key Insights for Investors

If you're evaluating Sun Pharmaceutical Industries Limited through a hard-nosed investor lens, start with the numbers: Q4FY25 total income of ₹13,571.71 crore (up 8% YoY) powered by India formulations growth of 13.6% and global specialty sales up 8.6%, while EBITDA surged 22.4% to deliver a robust 28.7% EBITDA margin; add to that an FY25 adjusted net profit of ₹119,844 million (+19% YoY), an average ROE of 15.21%, a conservative debt-to-equity of 0.46 with total debt at ₹5,000 crore against equity of ₹10,870 crore, strong liquidity (current ratio 2.89, quick ratio 1.5), operating cash flow of ₹12,134.98 crore and free cash flow of ₹3,500 crore, and you get a picture that raises as many strategic questions as it does confidence-how will a 2.5% decline in US formulations, regulatory risks, and product launch timing interact with valuation metrics (share price ₹1,683.25, market cap ₹403,952.04 crore, P/E 18.5) and near-term growth catalysts like Ilumya Phase 3 data, Leqselvi's expected launch and the Checkpoint acquisition; read on to unpack revenue mix, profitability drivers, balance-sheet strength, solvency, valuation, risks and opportunities in detail

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS) - Revenue Analysis

Q4FY25 topline: total income of ₹13,571.71 crore, up 8% year‑on‑year. Growth was driven by strong India formulations and global specialty performance, offset partially by weakness in the US generic portfolio.

• India formulations: +13.6% YoY; maintained leadership with an 8.3% market share.
• Global specialty sales: +8.6% YoY; accounted for 19.9% of Q4FY25 sales.
• US formulations: -2.5% in constant currency, pressured by generics despite specialty brand growth (Ilumya, Cequa).
• Emerging markets: +11.5% in constant currency, led by Romania, Russia and Brazil.
• Rest of World formulations: +2.0% YoY, indicating steady international performance.
• New product launches: 10 products in India and 10 in the US during Q4FY25, expanding the portfolio and addressing near‑term growth levers.

For a deeper look at shareholder composition and investor interest that complements these revenue dynamics, see Exploring Sun Pharmaceutical Industries Limited Investor Profile: Who's Buying and Why?

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS) - Profitability Metrics

Key profitability indicators for Sun Pharmaceutical Industries Limited reflect stronger margins, improved operational efficiency and steady growth in adjusted earnings across FY25 and Q4FY25.

• Q4FY25 EBITDA increased 22.4% year‑on‑year to deliver an EBITDA margin of 28.7%, showing improved operating leverage.
• Adjusted net profit for Q4FY25: ₹28,891 million, up 4.8% year‑on‑year.
• FY25 adjusted net profit: ₹119,844 million, up 19.0% year‑on‑year.
• Operating profit margin rose from 25.5% in FY24 to 27.2% in FY25, reflecting effective cost management.
• Net profit margin for FY25: 18.9% vs 14.4% in FY24.
• Average return on equity (ROE): 15.21%.

• Margin expansion (operating and net) signals better cost control and higher mix of profitable sales in FY25.
• EBITDA growth in Q4FY25 points to near‑term operational improvement despite segmental headwinds.
• ROE at 15.21% indicates efficient deployment of shareholders' capital versus historical peers.

For context on the company's strategic priorities that underpin these financial outcomes, see: Mission Statement, Vision, & Core Values (2026) of Sun Pharmaceutical Industries Limited.

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS) - Debt vs. Equity Structure

• Total debt: ₹5,000 crore
• Equity capital: ₹10,870 crore
• Debt-to-equity ratio: 0.46 (March 31, 2025)
• Consistent profit retention bolstering equity base
• Strong operating cash flows supporting debt servicing

• Conservative gearing leaves room for strategic acquisitions
• Profit retention policy has steadily increased shareholder equity
• Reduced refinancing risk due to manageable absolute debt levels

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS) - Liquidity and Solvency

• Current ratio: 2.89 - strong ability to cover short-term liabilities with current assets.
• Quick ratio (ex-inventory): 1.5 - adequate immediate liquidity without relying on inventory converts.
• Interest coverage ratio: 12.5 - operating profits sufficiently cover interest expense multiple times over.
• Solvency ratio (Total debt / Total assets): 0.15 - low financial leverage and reduced solvency risk.

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS) - Valuation Analysis

As of December 18, 2025, Sun Pharmaceutical Industries Limited (SUNPHARMA.NS) presented a valuation profile that combines market leadership with metrics suggesting relative attractiveness versus peers.

• Stock price: ₹1,683.25
• Market capitalization: ₹403,952.04 crore
• P/E ratio: 18.5 (industry average: 20)
• P/S ratio: 3.2
• EV/EBITDA: 12
• Dividend per share: ₹5.5
• Dividend yield: 1.5%
• Recognition: Included in S&P Global Sustainability Yearbook 2025

Key valuation takeaways:

• P/E below industry average suggests relative undervaluation on earnings multiple, offering potential upside if growth/recovery materializes.
• P/S and EV/EBITDA sit within typical sector ranges, indicating the market's view of Sun Pharma's revenue and operating profitability are reasonable.
• Dividend yield of 1.5% alongside a ₹5.5 DPS signals steady shareholder returns but not a high-income play.
• ESG recognition (S&P Global Sustainability Yearbook 2025) can attract sustainability-focused capital and marginally support valuation multiples.

For additional context on the company's strategic direction and non-financial priorities, see: Mission Statement, Vision, & Core Values (2026) of Sun Pharmaceutical Industries Limited.

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS) - Risk Factors

• US formulations slowdown: a 2.5% decline in constant currency signals headwinds in the generics franchise and pricing pressure in the US market, which historically contributes roughly 25-35% of consolidated revenue.
• Regulatory risk: shifting FDA/EMA guidance, increased inspection activity or new approval standards can delay launches or lead to additional remediation costs for manufacturing sites.
• Currency volatility: exposure to INR/US$ and several emerging-market currencies can compress margins; exchange moves of ±5-10% historically translate to multi-percentage-point swings in reported EBITDA for multinational pharma groups.
• Competitive intensity: low-cost generics manufacturers and biosimilar entrants can erode market share and compress pricing in key molecules.
• Product launch delays: postponement of key launches (example: Leqselvi follow-on launches or other specialty product rollouts) can defer expected revenue trajectories and R&D payback timelines.
• Legal and compliance exposures: patent litigations, product liability suits and antitrust scrutiny can generate one-off charges, injunctions and higher legal reserves.

• Magnitude and timing: the combined effect of multiple risks occurring simultaneously (for example, a regulatory setback in the US during a period of adverse currency moves and heightened competition) can produce non-linear impacts-short-term revenue shocks and margin deterioration followed by longer-term increased capex/compliance spending.
• Balance sheet and liquidity buffers: key mitigants include cash reserves, revolving credit availability and the company's ability to re-prioritize R&D/capex; stress scenarios assume slower cash conversion and potential pressure on free cash flow for a 6-18 month window.
• Monitoring indicators: FDA inspection outcomes, quarterly US formulations volume/pricing trends, currency movement vs. INR, timing of specialty product approvals, and litigation disclosures in regulatory filings.

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS) - Growth Opportunities

• Ilumya (immunology): Phase 3 data readout expected in H2 CY25 - a successful outcome would materially de‑risk launch and support meaningful specialty sales growth.
• Leqselvi: Launch now expected in Q2 FY26; commercial rollout should add to top‑line from FY26 onward once distribution and physician adoption scale.
• Checkpoint Therapeutics acquisition: Strengthens oncology portfolio and creates incremental oncology revenue streams and cross‑sell opportunities into existing markets.
• Emerging market expansion: Targeted growth in Romania, Russia and Brazil to bolster ex‑US/India diversification and leverage established generics and specialty channels.
• Global specialty sales momentum: Specialty segment grew 8.6% YoY in Q4 FY25 - continued outperformance here can lift consolidated margins due to higher ASPs and better gross margins.
• R&D commitment: R&D spend of ₹8,166 million in Q4 FY25 underpins pipeline progression and future molecule launches.

• Commercial execution risks: Market access, pricing pressure in key markets, and physician uptake timelines will determine realized revenue versus modeled upside.
• Regulatory and clinical risk: Ilumya Phase 3 outcomes and any label/approval delays directly affect near‑term valuation of the immunology franchise.
• Integration risk: Realizing Checkpoint synergies depends on effective integration and successful US oncology commercialization.